PCM
AST

Poehling Capital Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Poehling Capital Management’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,302
Closed -$4K – 306
2018
Q2 		$4K Hold
3,302
– – ﹤0.01% 256
2018
Q1 		$5K Buy
3,302
+500
+18% +$1.04K ﹤0.01% 258
2017
Q4 		$6K Buy
+2,802
New +$7.09K 0.01% 234

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Poehling Capital Management's AST Position: Q3 2018 in Review

Poehling Capital Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2018, closing a stake of 3,302 shares — an estimated $4K sold.

Poehling Capital Management first reported a position in AST in Q4 2017 and held it in 3 quarters. The position peaked at $6K in Q4 2017. 54 funds tracked by Wall St. Rank hold AST as of Q3 2018.

  • Poehling Capital Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2018 after selling out during the quarter.
  • Poehling Capital Management sold 3,302 Asterias Biotherapeutics Inc. Series A shares in Q3 2018, an estimated $4K.
  • Poehling Capital Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2017 and held it in 3 quarters.
  • Poehling Capital Management's Asterias Biotherapeutics Inc. Series A position peaked at $6K in Q4 2017.
  • 54 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2018.

Based on Poehling Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.